Latest: FDA Approves New Biosimilar for Oncology Treatment

STAT+: U.S. warning on use of ‘march-in’ rights against Harvard seems like distant threat for pharma

0 Mins
A recent U.S. warning on use of 'march-in' rights against Harvard University seems like distant threat for pharma. Here's why.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago